News & Events
- LUCA Biologics Launches to Develop Live Biotherapeutics for Women’s Health Starting with Urinary Tract Infection (UTI)
- Seres Therapeutics Reports Second Quarter Financial Results and Provides Progress Update
- Seres Therapeutics Appoints Stephen Berenson to its Board of Directors
- Seres Therapeutics to Present at the Canaccord Genuity 39th Annual Growth Conference
- Seres Therapeutics to Host Second Quarter 2019 Financial Results and Operational Progress Conference Call and Webcast on August 6, 2019
- Seed Health Joins Microbiome Therapeutics Innovation Group
- Rebiotix Leaders to Discuss Microbiome Product Development Challenges and Regulation at Microbiome Movement – Drug Development Summit 2019
- Vedanta Biosciences Announces First Patient Enrolled in VE416 Phase 1b/2 Food Allergy Clinical Study
- Vedanta Biosciences’ Silvia Caballero, Ph.D., Named as an MIT Technology Review Global Innovator Under 35
- Seres Therapeutics Issues Statement Regarding U.S. Food and Drug Administration Safety Alert Related to Use of Fecal Microbiota Transplantation
- Microbiome Therapeutics Innovation Group Statement on FDA Safety Alert Regarding Use of Fecal Microbiota for Transplantation and Risk of Serious Adverse Reactions Due to Transmission of Multi-Drug Resistant Organisms
- Seres Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock
- Seres Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
- Seres Therapeutics to Present at the Jefferies 2019 Healthcare Conference
- Microbiota Restoration Takes the Podium at DDW 2019: Investigational Microbiota-Based Therapies for Recurrent C. diff Highlighted